Treatment of Geographic Atrophy With Subconjunctival Sirolimus: Results of a Phase I/II Clinical Trial | Zendy

Wai T. Wong | Zendy; Samuel M. Dresner | Zendy; Farzin Forooghian | Zendy; Tanya Glaser | Zendy; Lauren E. Doss | Zendy; Mei Zhou | Zendy; Denise Cunningham | Zendy; Katherine Hall Shimel | Zendy; Molly Harrington | Zendy; Keri Hammel | Zendy; Catherine A. Cukras | Zendy; Frederick L. Ferris | Zendy; Emily Y. Chew | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of Geographic Atrophy With Subconjunctival Sirolimus: Results of a Phase I/II Clinical Trial

Author(s) -

Wai T. Wong,

Samuel M. Dresner,

Farzin Forooghian,

Tanya Glaser,

Lauren E. Doss,

Mei Zhou,

Denise Cunningham,

Katherine Hall Shimel,

Molly Harrington,

Keri Hammel,

Catherine A. Cukras,

Frederick L. Ferris,

Emily Y. Chew

Publication year - 2013

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.13-11650

Subject(s) - medicine , drusen , sirolimus , visual acuity , geographic atrophy , ophthalmology , macular degeneration , adverse effect , clinical trial , randomized controlled trial , retinal , surgery

To investigate the safety and effects of subconjunctival sirolimus, an mTOR inhibitor and immunosuppressive agent, for the treatment of geographic atrophy (GA).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research